ATE95069T1 - Durch antikoerper und liganden bewirkte zielrichtung von differentiationsinduktoren auf tumorzellen. - Google Patents

Durch antikoerper und liganden bewirkte zielrichtung von differentiationsinduktoren auf tumorzellen.

Info

Publication number
ATE95069T1
ATE95069T1 AT89305461T AT89305461T ATE95069T1 AT E95069 T1 ATE95069 T1 AT E95069T1 AT 89305461 T AT89305461 T AT 89305461T AT 89305461 T AT89305461 T AT 89305461T AT E95069 T1 ATE95069 T1 AT E95069T1
Authority
AT
Austria
Prior art keywords
tumor cells
targeting
ligands
antibodies
differentiation
Prior art date
Application number
AT89305461T
Other languages
English (en)
Inventor
Sen-Itiroh Hakomori
Michiro Otako
Anil Singhal
Original Assignee
Biomembrane Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomembrane Inst filed Critical Biomembrane Inst
Application granted granted Critical
Publication of ATE95069T1 publication Critical patent/ATE95069T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT89305461T 1988-07-01 1989-05-31 Durch antikoerper und liganden bewirkte zielrichtung von differentiationsinduktoren auf tumorzellen. ATE95069T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21426188A 1988-07-01 1988-07-01
EP89305461A EP0349127B1 (de) 1988-07-01 1989-05-31 Durch Antikörper und Liganden bewirkte Zielrichtung von Differentiationsinduktoren auf Tumorzellen

Publications (1)

Publication Number Publication Date
ATE95069T1 true ATE95069T1 (de) 1993-10-15

Family

ID=22798404

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89305461T ATE95069T1 (de) 1988-07-01 1989-05-31 Durch antikoerper und liganden bewirkte zielrichtung von differentiationsinduktoren auf tumorzellen.

Country Status (5)

Country Link
EP (1) EP0349127B1 (de)
JP (1) JPH02142489A (de)
AT (1) ATE95069T1 (de)
CA (1) CA1336760C (de)
DE (1) DE68909515T2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9112212D0 (en) * 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
US5846951A (en) * 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
US7166295B1 (en) 1995-05-26 2007-01-23 Meir Strahilevitz Methods of treatment and diagnostic visualization, particularly in cancer
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US7348025B2 (en) 1997-09-23 2008-03-25 Research Development Foundation Small particle liposome aerosols for delivery of anticancer drugs
EP2255787A4 (de) * 2008-02-22 2014-08-27 Katayama Chemical Ind Co Ltd Synthetische glycolipidhaltige liposomen

Also Published As

Publication number Publication date
DE68909515D1 (de) 1993-11-04
DE68909515T2 (de) 1994-03-03
CA1336760C (en) 1995-08-22
EP0349127B1 (de) 1993-09-29
JPH02142489A (ja) 1990-05-31
EP0349127A1 (de) 1990-01-03

Similar Documents

Publication Publication Date Title
DE3888186D1 (de) Modulärer zusammenbau von antikörpergenen, dadurch hergestellte antikörper und deren anwendung.
DE69330643D1 (de) Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon
ATE243754T1 (de) Multifunktionelle proteine mit vorbestimmter zielsetzung
US5260274B1 (en) Factor VIII binding domain of von willebrand factor
DK0724456T3 (da) CD40-Antistoffer
DK96588D0 (da) Antitumirmiddel indeholdende makromolekylaere platinforbindelser
ATE81153T1 (de) Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern.
DE68918217D1 (de) Familie von modifizierten Antikörpern mit hoher Affinität zur Behandlung von Krebs.
ATE162079T1 (de) Verwendung von antikörper enthaltenden präparationen zur immunsuppression
BG40318A3 (en) Method for preparing imunoglobuline derivatives of vindezine
NO873271D0 (no) Apolipoprotein b-spesifikke monoklonale antistoffer produsert av to nye hybridomer.
DE68909515D1 (de) Durch antikoerper und liganden bewirkte zielrichtung von differentiationsinduktoren auf tumorzellen.
DE3586216D1 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
DE3581288D1 (de) Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
DE59209839D1 (de) Monoklonalantikörper, Linker- und Beta-Glucuronidase enthaltende Fusionsproteine zur Prodrug-Aktivierung, ihre Herstellung und Verwendung
ATE58172T1 (de) Monoklonale antikoerper gegen alpha-2 interferon und hybridomas, die solche antikoerper produzieren.
DE3582386D1 (de) Menschlicher, monoklonaler antikoerper und seine herstellung.
DK0672685T3 (da) Monoklonalt antistof specifik for tumor cytotoxisk faktor (TCF-11)
ATE169962T1 (de) Monoklonaler anti-gangliosid-antikörper, seine herstellung und verwendung als tumortherapeutikum
ATE56617T1 (de) Anti-urokinase monoklonaler antikoerper, seine herstellung und verwendung.
DE3877015D1 (de) Antikoerper enthaltende stabilisierte waesserige zusammensetzung.
ATE92081T1 (de) Tumorassoziiertes antigen.
ATE34970T1 (de) Neue d-mannit-abkoemmlinge als vorprodukte zur synthese von phospholipiden.
ATE84318T1 (de) Monoklonale antikoerper, spezifisch von in vivo von fibrinogen abgeleiteten derivatstuecken.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee